Managed Care Weekly Digest
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Weekly Digest
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cardiac Medical Devices
Ventracor trial results show left ventricular assist device had 83% success rate
October 9th, 2006
Clinical results of the VentrAssist left ventricular assist device (LVAD) CE Mark Bridge-to-Transplant Trial, presented at the European Association of Cardiothoracic Surgeons (EACTS) in Sweden, showed an 83% success rate of the LVAD, which is significantly better than the earlier published results of first generation devices, reported to be 65%. The primary clinical end-point of the trial was cardiac transplant or continued transplant eligible at 154 days after a VentrAssist implant. The adverse event rate was in line with expectations. The purpose of Ventracor's CE Mark Trial was to establish clinical performance of the...
Source: Managed Care Weekly Digest (2006-10-09)
|
